| Name | Title | Contact Details |
|---|
Samumed is a leader in medical research and development for tissue-level regeneration. With our platform`s origins in small molecule-based Wnt pathway modulation, we develop therapeutics to address a range of degenerative diseases, regenerative medicine and oncology.
Quintiles is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Absci is the AI-powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. We built our Integrated Drug Creation™ Platform to accelerate discovery of novel biotherapeutic drug candidates and generation of the cell lines to manufacture them in a single efficient process. Biotech and pharma innovators partner with us to develop new protein-based drugs, including those that may be impossible to make with other technologies. Our goal is to enable the creation of better medicines by Translating Ideas into Drugs.
Ultragenyx is a clinical-stage biotechnology company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. Founded in 2010, the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no approved therapies. Our company is led by an experienced management team in rare disease therapeutics. Recognizing that our primary responsibility is to our patients, we are working with advocacy groups to provide support and outreach to individuals and families affected by these disorders and engage them in the clinical testing process. We are also working with regulatory agencies to design and conduct high quality clinical studies that meet the requirements for approval. We are creating an improved model for successful rare disease drug development that increases efficiency and effectiveness by changing the way the process is organized and conducted. We believe that we can deliver significant value to our patients by building a diverse and high quality pipeline of rare disease therapeutics and efficiently transforming good science into great medicine. We are looking for highly motivated individuals to join our team in an exciting biotechnology environment. If you are looking for a meaningful position that has the ability to transform the lives of patients and be part of a high performance team focused on the same goal, this is the opportunity you have been waiting for.
AuraSense Therapeutics (AST) is a biopharmaceutical company developing first-in-class therapies based upon its proprietary Spherical Nucleic Acid (SNA) gene regulation and immune modulation strategies. AST is leading the translation of SNA constructs as innovative medicines with a core focus on debilitating diseases with limited or no treatment options. AuraSense Therapeutics' uniquely engineered SNA™ constructs possess attractive biocompatibility and versatility as therapeutics and hold great promise for combating the most life-threatening diseases, including many forms of cancer, infectious disease, and skin conditions.